ClinicalTrials.gg
CompletedNCT02077465Updated Sep 9, 2020Results posted

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 1 interventional study of Andecaliximab and Placebo to match Andecaliximab in Chronic Obstructive Pulmonary Disease, sponsored by Gilead Sciences. Completed at 5 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
920th of 1,037
11 · median 100
Started
2014
with 69 others
Phase 1
91 of 1,278
5 open now
Registered
577th of 1,278
by date

Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 920th largest by enrollment of the 1,037 interventional ones that give a count, is one of 70 that started in 2014, is one of 91 in phase 1, and was the 577th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD, chronic obstructive pulmonary disease; Safety, Pharmacokinetics
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Weight: ≥ 45 kg to \< 120 kg at screening
  • Males or non-pregnant, non-lactating females
  • Male individuals and female individuals of who engage in heterosexual intercourse must agree to use protocol specified method(s) of . Male individuals must refrain from sperm donation for 90 days post last infusion of the study drug
  • Diagnosis of per Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for at least 6 months prior to screening and anticipated to remain on stable therapy for the duration of the study
  • Post-bronchodilator (FEV1) ≥ 40% predicted
  • No changes in COPD medications within 30 days prior to randomization
  • Hepatic panel [ (AST), alanine aminotransferase (ALT), total , direct bilirubin, alkaline phosphatase, lactate dehydrogenase (LDH)] ≤ 2 times the (ULN)
  • Serum creatinine ≤ 2.0
  • ≥ 8.5 g/dL (both males and females)
  • (ANC) ≥ 1.5 x 10\^9/L (1,500 mm\^3)
  • ≥ 100 x 10\^9/L

Key Exclusion Criteria:

  • active infection as judged by the investigator during screening
  • Known history of , or C during screening. Individuals who are hepatitis B surface antigen positive, but who received a successful series of hepatitis B vaccinations and never had the disease remain eligible
  • A positive QuantiFERON-TB GOLD test during screening
  • History of within the last 5 years except for patients who have been treated locally for non-melanoma skin cancer or cervical carcinoma in situ
  • Any serious cardiac event such as myocardial infarction, unstable or life-threatening arrhythmia, hospitalization for cardiac failure within 6 months prior to randomization or any significant or new (ECG) finding at Visit 1 as judged by the Investigator
  • A hospitalization for a respiratory event such as, but not limited to, COPD, pneumonia, bronchiolitis, within the previous 6 months prior to randomization
  • Chronic lung disease other than COPD such as: asthma, cystic fibrosis or fibrotic disease, α-1-antitrypsin deficiency, interstitial lung disease, pulmonary thromboembolic disease, or bronchiectasis
  • Chronic use of systemic and/or treatment with systemic corticosteroids for an acute exacerbation of COPD (AECOPD) event, or other medical condition not requiring hospitalization, within 90 days of randomization.
  • Treatment with antibiotics for an AECOPD event, or other medical condition not requiring hospitalization within 90 days of randomization, or any minor medical event not requiring hospitalization within 14 days of randomization.
  • Treatment with any marketed or biologic within 5 half-lives of the molecule or if unknown within 90 days of screening
  • Individuals currently on nonbiologic immune modulator medications such as: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate mofetil, sulfasalazine, tofacitinib, within 90 days of randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Andecaliximab

    Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.

    Drug: Andecaliximab

  • Placebo comparator
    Placebo to match andecaliximab

    Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.

    Drug: Placebo to match Andecaliximab

Interventions

  • 400 mg andecaliximab administered intravenously

    Also known as: GS-5745

  • DrugPlacebo to match Andecaliximab

    Placebo to match andecaliximab administered intravenously

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time frame: First dose date up to Day 29 plus 30 days

  2. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug and within 30 days after last study drug administration. The severity of laboratory abnormalities was assessed as Grade 0, 1 (mild), 2 (moderate), 3 (severe), or 4 (potentially life threatening) using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: First dose date up to Day 29 plus 30 days

  3. Percentage of Participants Who Developed Anti-andecaliximab Antibodies

    The presence of anti-andecaliximab antibodies in serum samples was determined using an electrochemiluminescent (ECL) assay that detects antibodies that bind to andecaliximab.

    Time frame: Day 43

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter of Andecaliximab: AUClast for Days 1, 15 and 29

    AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes

  2. PK Parameter of Andecaliximab: AUCinf for Day 1

    AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

  3. PK Parameter of Andecaliximab: %AUCexp for Day 1

    %AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

  4. PK Parameter of Andecaliximab: Cmax for Days 1, 15 and 29

    Cmax is defined as the maximum observed plasma concentration of drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes

  5. PK Parameter of Andecaliximab: Tmax for Days 1, 15 and 29

    Tmax is defined as the time (observed time point) of Cmax. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes

  6. PK Parameter of Andecaliximab: Clast for Days 1, 15 and 29

    Clast is defined as the last observable concentration of drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes

  7. PK Parameter of Andecaliximab: Tlast for Days 1, 15 and 29

    Tlast is defined as the time (observed time point) of Clast. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes

  8. PK Parameter of Andecaliximab: λz for Day 1

    λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

  9. PK Parameter of Andecaliximab: CL for Day 1

    Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

  10. PK Parameter of Andecaliximab: Vz for Day 1

    Vz is defined as the volume of distribution of the drug after intravenous administration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

  11. PK Parameter of Andecaliximab: Vss for Day 1

    Vss is defined as the volume of distribution of the drug at steady state after intravenous administration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

  12. PK Parameter of Andecaliximab: t1/2 for Day 1

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

    Time frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes

07

Results

Posted Aug 13, 2020

Participant flow

Participants were enrolled at study sites in United States. The first participant was screened on 11 March 2014. The last study visit occurred on 27 October 2014.

Participant flow — Overall Study
MilestoneAndecaliximabPlacebo
Started83
Completed72
Not completed11
Withdrew: Withdrew consent01
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame:
First dose date up to Day 29 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
percentage of participantsAndecaliximabPlacebo
Percentage of Participants Experiencing Treatment-Emergent Adverse Events75.033.3
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug and within 30 days after last study drug administration. The severity of laboratory abnormalities was assessed as Grade 0, 1 (mild), 2 (moderate), 3 (severe), or 4 (potentially life threatening) using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
First dose date up to Day 29 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
percentage of participantsAndecaliximabPlacebo
Any Post-Baseline Toxicity Grade87.5100.0
Grade 175.0100.0
Grade 212.50.0
Grade 30.00.0
Grade 40.00.0
PrimaryPercentage of Participants Who Developed Anti-andecaliximab Antibodies

The presence of anti-andecaliximab antibodies in serum samples was determined using an electrochemiluminescent (ECL) assay that detects antibodies that bind to andecaliximab.

Time frame:
Day 43
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed Anti-andecaliximab Antibodies
percentage of participantsAndecaliximab
Day 43 Positive Anti-Drug Antibody (ADA) Response12.5
Day 43 Negative ADA Response75.0
Unknown (no ADA sample available)12.5
SecondaryPharmacokinetic (PK) Parameter of Andecaliximab: AUClast for Days 1, 15 and 29

AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
Reported as:
Mean · day*ug/mL
Pharmacokinetic (PK) Parameter of Andecaliximab: AUClast for Days 1, 15 and 29
day*ug/mLAndecaliximab
Day 11206.7 ± 357.75
Day 151880.5 ± 600.33
Day 291822.2 ± 283.39
SecondaryPK Parameter of Andecaliximab: AUCinf for Day 1

AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · day*ug/mL
PK Parameter of Andecaliximab: AUCinf for Day 1
day*ug/mLAndecaliximab
PK Parameter of Andecaliximab: AUCinf for Day 11398.1 ± 265.26
SecondaryPK Parameter of Andecaliximab: %AUCexp for Day 1

%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · percentage of AUC
PK Parameter of Andecaliximab: %AUCexp for Day 1
percentage of AUCAndecaliximab
PK Parameter of Andecaliximab: %AUCexp for Day 119.97 ± 12.781
SecondaryPK Parameter of Andecaliximab: Cmax for Days 1, 15 and 29

Cmax is defined as the maximum observed plasma concentration of drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
Reported as:
Mean · ug/mL
PK Parameter of Andecaliximab: Cmax for Days 1, 15 and 29
ug/mLAndecaliximab
Day 1236.7 ± 62.70
Day 15255.9 ± 71.25
Day 29270.6 ± 46.48
SecondaryPK Parameter of Andecaliximab: Tmax for Days 1, 15 and 29

Tmax is defined as the time (observed time point) of Cmax. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
Reported as:
Mean · day
PK Parameter of Andecaliximab: Tmax for Days 1, 15 and 29
dayAndecaliximab
Day 10.08 ± 0.076
Day 150.02 ± 0.000
Day 290.02 ± 0.001
SecondaryPK Parameter of Andecaliximab: Clast for Days 1, 15 and 29

Clast is defined as the last observable concentration of drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
Reported as:
Mean · ug/mL
PK Parameter of Andecaliximab: Clast for Days 1, 15 and 29
ug/mLAndecaliximab
Day 137.07 ± 18.740
Day 1550.27 ± 14.724
Day 2971.74 ± 23.905
SecondaryPK Parameter of Andecaliximab: Tlast for Days 1, 15 and 29

Tlast is defined as the time (observed time point) of Clast. Data for Day 1 was generated based on the data collected from Day 1 through Day 15. Data for Day 15 was generated based on the data collected from Day 15 through Day 29. Data for Day 29 was generated based on the data collected from Day 29 through Day 43.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
Reported as:
Mean · day
PK Parameter of Andecaliximab: Tlast for Days 1, 15 and 29
dayAndecaliximab
Day 112.96 ± 2.582
Day 1514.79 ± 1.737
Day 2913.45 ± 1.379
SecondaryPK Parameter of Andecaliximab: λz for Day 1

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · 1/day
PK Parameter of Andecaliximab: λz for Day 1
1/dayAndecaliximab
PK Parameter of Andecaliximab: λz for Day 10.137 ± 0.0263
SecondaryPK Parameter of Andecaliximab: CL for Day 1

Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · mL/day
PK Parameter of Andecaliximab: CL for Day 1
mL/dayAndecaliximab
PK Parameter of Andecaliximab: CL for Day 1296.5 ± 64.67
SecondaryPK Parameter of Andecaliximab: Vz for Day 1

Vz is defined as the volume of distribution of the drug after intravenous administration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · mL
PK Parameter of Andecaliximab: Vz for Day 1
mLAndecaliximab
PK Parameter of Andecaliximab: Vz for Day 12200.9 ± 442.03
SecondaryPK Parameter of Andecaliximab: Vss for Day 1

Vss is defined as the volume of distribution of the drug at steady state after intravenous administration. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · mL
PK Parameter of Andecaliximab: Vss for Day 1
mLAndecaliximab
PK Parameter of Andecaliximab: Vss for Day 12178.7 ± 450.66
SecondaryPK Parameter of Andecaliximab: t1/2 for Day 1

t1/2 is defined as the estimate of the terminal elimination half-life of the drug. Data for Day 1 was generated based on the data collected from Day 1 through Day 15.

Time frame:
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
Reported as:
Mean · day
PK Parameter of Andecaliximab: t1/2 for Day 1
dayAndecaliximab
PK Parameter of Andecaliximab: t1/2 for Day 15.24 ± 1.102

Adverse events

Collected over First dose date up to Day 29 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andecaliximab0/8 (0%)0/8 (0%)6/8 (75%)
Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAndecaliximabPlacebo
Upper respiratory tract infectionInfections and infestations0/81/3
AnaemiaBlood and lymphatic system disorders1/80/3
NauseaGastrointestinal disorders1/80/3
VomitingGastrointestinal disorders1/80/3
PainGeneral disorders1/80/3
Urinary tract infectionInfections and infestations1/80/3
Ligament sprainInjury, poisoning and procedural complications1/80/3
Periorbital contusionInjury, poisoning and procedural complications1/80/3
Blood creatine phosphokinase increasedInvestigations1/80/3
Electrocardiogram QT prolongedInvestigations1/80/3

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 infusion of study drug (andecaliximab or placebo).

Age, Continuous
Age, Continuous(years)AndecaliximabPlaceboTotal
Mean65 ± 3.356 ± 3.562 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)AndecaliximabPlaceboTotal
Female516
Male325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AndecaliximabPlaceboTotal
Black213
White628
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AndecaliximabPlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino729
08

Study locations

5 sites
  • Advanced Pharma CR, LLC
    Miami, Florida 33136, United States
  • Elite Research Institute
    Miami, Florida 33169, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • University at Buffalo CTRC
    Buffalo, New York 14203, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Oct 2014, 7 months.

Results were first posted in Aug 2020, 5 years 9 months after primary completion.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 7 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2014
First posted
Mar 4, 2014
StartActual
Mar 11, 2014
Primary completionActual
Oct 27, 2014
CompletionActual
Oct 27, 2014
Results first posted
Aug 13, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02077465
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 4, 2014
Start date
Mar 11, 2014
Primary completion
Oct 27, 2014
Completion
Oct 27, 2014
Results posted
Aug 13, 2020
Last update
Sep 9, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion